Business Context and Reporting Period
This Form 6-K filing by Nano-X Imaging Ltd. covers the month of June 2024, with a specific reporting date of June 13, 2024. The document serves as a report of a foreign private issuer under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance updates rather than financial performance.
Material Changes
The primary material change disclosed is the appointment of a new director to the Board of Directors.
- Appointment: Mr. Michael Jackman was appointed as a member of the Board.
- Effective Date: July 1, 2024.
- Status: Determined to be an independent director in accordance with Nasdaq listing rules.
Management Commentary and Risks
The filing provides biographical details regarding Mr. Jackman's extensive background in healthcare technology and operations, including roles as COO of Leidos Health Group, CEO of Mach7 Technologies, and senior executive positions at GE Healthcare, Carestream Health, and IBM. No specific risks, contingencies, unusual items, or forward-looking guidance regarding financial performance are included in this document.
Key Facts for Investor Verification
- Verify the effective date of Mr. Jackman's board membership (July 1, 2024).
- Confirm Mr. Jackman's independence status under Nasdaq listing rules.
- Note that this filing contains no financial data; investors should refer to recent Form 20-F or quarterly reports for financial metrics.